Clinical Development Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Clinical Development stocks.

Clinical Development Stocks Recent News

Date Stock Title
Nov 22 BLRX BioLineRx Q3 2024 Earnings Preview
Nov 22 LXRX Lexicon Pharmaceuticals to Cut 60% of Workforce
Nov 22 LXRX Lexicon falls on restructuring program
Nov 22 LXRX Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Nov 22 SAGE Sage Therapeutics price target lowered to $4 from $7 at BofA
Nov 22 BLRX BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
Nov 21 SAGE Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
Nov 21 SAGE Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Nov 21 SAGE Sage ends dalzanemdor development following Phase II trial failure
Nov 21 SAGE SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
Nov 21 SAGE Sage raised to sector perform by RBC in wake of drug failure
Nov 21 BLRX BioLineRx inks licensing deal, share purchase agreement
Nov 21 BLRX BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
Nov 20 LXRX Lexicon Appoints Ivan H. Cheung to Board of Directors
Nov 20 SAGE After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
Nov 20 SAGE Sage slips as Huntington’s Disease therapy fails in mid-stage trial
Nov 20 BLRX BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Nov 20 SAGE Sage’s string of research failures continues
Nov 20 SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
Nov 19 SAGE CNS Drug Development: Same As It Ever Was
Clinical Development

Clinical development is the process of developing a new drug, medical device, or diagnostic test from the initial concept to the point of regulatory approval. It involves a series of steps, including preclinical research, clinical trials, regulatory review, and post-marketing surveillance. The goal of clinical development is to demonstrate the safety and efficacy of a product in order to obtain regulatory approval for marketing.

Browse All Tags